ANX Mast Therapeutics, Inc.

SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced today that Brian M. Culley, ADVENTRX's chief business officer and senior vice president, will present a company overview at the upcoming Biotechnology Industry Organization (BIO) Annual Meeting in Boston. Mr. Culley is scheduled to present on Tuesday, May 8 at 9:30 a.m. Eastern Time. The conference takes place May 6-9, 2007. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. The Company's lead product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer. More information can be found on ADVENTRX's web site at http://www.adventrx.com/. Forward Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866; or Media, Edie DeVine of WeissComm Partners, +1-415-946-1081, for ADVENTRX Pharmaceuticals Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright